Seattle Children’s Hospital

4800 Sand Point Way, NE

Seattle, WA 98105

United States

Enhancing CAR T Cell Therapy for Diffuse Intrinsic Pontine Glioma by Promoting CAR T Cell Persistence with Novel Manufacturing Approach and Immune Checkpoint Receptor Modifications

Brain Tumors, Diffuse Intrinsic Pontine Glioma (DIPG)

My research at Seattle Children’s is to develop and improve a new type of cellular therapy to treat children’s brain cancers, and we call this new treatment CAR T cell therapy, in which we genetically modify patients’ own immune cells so that they could directly recognize and kill cancer cells.

Edward Song, PhD

Seattle Children’s Hospital

Epigenetic Targeting of Translation in Sarcomas

Osteosarcoma, Rhabdomyosarcoma

Mentor Name: Jay Sarthy

Thanh Van Nguyen

Seattle Children’s Hospital

Uncovering the oncogenic properties of ZNF384 fusion proteins in leukemia

Leukemia

Mentor Name: Clara Libbrecht

Aimee Li

Seattle Children’s Hospital

Building a Therapeutic Atlas of Pediatric Brain Tumor Vascular Proteins

Brain Tumors

Mentor Name: Shireen Ganapathi

Cindy Wang

Seattle Children’s Hospital

Andras Heczey, MD

Seattle Children’s Hospital

Targeting Chromatin-Remodeling Complexes in ZNF384-rearranged Mixed Phenotype Acute Leukemia.

Leukemia

Mixed Phenotype Acute Leukemia (MPAL) is an understudied subtype of leukemia that shares features of acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML). Unfortunately, patients with MPAL have been left out of clinical trials, leading to a lack of standardized treatment. Instead, they may receive chemotherapies normally used for ALL or AML, and their outcomes remain poor. A better understanding of the disease is essential to design more efficient and targeted therapies. Rearrangements of the ZNF384 gene are a common genetic change in childhood MPAL.

Alex's Lemonade Stand Foundation for Childhood Cancer